Rna Diagnostics closes $5 mln Series A led by iGan Partners

Rna Diagnostics Inc, a Toronto-based cancer therapy guidance platform, has raised $5 million in a Series A financing. The round was led by Canadian early-stage venture capital firm iGan Partners. It was joined by undisclosed new and existing investors. Founded in 2010, Rna Diagnostics’ first product is the RNA Disruption Assay, a diagnostic test that helps physicians to rapidly assess how patients are responding to cancer treatments. President and CEO Jeremy Bridge-Cook said the funds raised will support the technology's clinical trial in primary breast cancer as well as commercialization initiatives. Bridge-Cook formerly served as an investment manager with MDS Capital Corp.

CanadaNorth AmericaBriefs